PL3813816T3 - Zastosowanie kwasu (s)-3-amino-4-(difluorometylenylo)cyklopentano-1-eno-1-karboksylowego i związków pokrewnych, kwasu (1s,3s)-3-amino-4-(difluorometylideno)cyklopentano-1-karboksylowego w leczeniu zespołu łamliwego chromosomu x lub zespołu drżenia/ataksji związanego z zespołem łamliwego chromosomu x - Google Patents

Zastosowanie kwasu (s)-3-amino-4-(difluorometylenylo)cyklopentano-1-eno-1-karboksylowego i związków pokrewnych, kwasu (1s,3s)-3-amino-4-(difluorometylideno)cyklopentano-1-karboksylowego w leczeniu zespołu łamliwego chromosomu x lub zespołu drżenia/ataksji związanego z zespołem łamliwego chromosomu x

Info

Publication number
PL3813816T3
PL3813816T3 PL19815892.5T PL19815892T PL3813816T3 PL 3813816 T3 PL3813816 T3 PL 3813816T3 PL 19815892 T PL19815892 T PL 19815892T PL 3813816 T3 PL3813816 T3 PL 3813816T3
Authority
PL
Poland
Prior art keywords
fragile
amino
carboxylic acid
syndrome
difluoromethylenyl
Prior art date
Application number
PL19815892.5T
Other languages
English (en)
Inventor
Matthew During
Brett Abrahams
Original Assignee
Ovid Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc. filed Critical Ovid Therapeutics Inc.
Publication of PL3813816T3 publication Critical patent/PL3813816T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL19815892.5T 2018-06-07 2019-06-07 Zastosowanie kwasu (s)-3-amino-4-(difluorometylenylo)cyklopentano-1-eno-1-karboksylowego i związków pokrewnych, kwasu (1s,3s)-3-amino-4-(difluorometylideno)cyklopentano-1-karboksylowego w leczeniu zespołu łamliwego chromosomu x lub zespołu drżenia/ataksji związanego z zespołem łamliwego chromosomu x PL3813816T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862681913P 2018-06-07 2018-06-07
PCT/US2019/035934 WO2019236938A1 (en) 2018-06-07 2019-06-07 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Publications (1)

Publication Number Publication Date
PL3813816T3 true PL3813816T3 (pl) 2023-07-31

Family

ID=68765508

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19815892.5T PL3813816T3 (pl) 2018-06-07 2019-06-07 Zastosowanie kwasu (s)-3-amino-4-(difluorometylenylo)cyklopentano-1-eno-1-karboksylowego i związków pokrewnych, kwasu (1s,3s)-3-amino-4-(difluorometylideno)cyklopentano-1-karboksylowego w leczeniu zespołu łamliwego chromosomu x lub zespołu drżenia/ataksji związanego z zespołem łamliwego chromosomu x

Country Status (12)

Country Link
US (3) US10813899B2 (pl)
EP (1) EP3813816B1 (pl)
JP (1) JP7387179B2 (pl)
KR (1) KR102744830B1 (pl)
CN (1) CN112770739B (pl)
AU (1) AU2019280980B2 (pl)
CA (1) CA3102786A1 (pl)
ES (1) ES2948263T3 (pl)
IL (2) IL279220B2 (pl)
MX (2) MX2020013290A (pl)
PL (1) PL3813816T3 (pl)
WO (1) WO2019236938A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3813816B1 (en) 2018-06-07 2023-06-07 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
GB2591389A (en) 2018-08-18 2021-07-28 Ftf Pharma Private Ltd Pharmaceuticals solution for oral dosage
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition
IL322803A (en) * 2023-02-17 2025-10-01 Ovid Therapeutics Inc Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and prediabetes
EP4648757A4 (en) * 2023-02-17 2026-01-07 Ovid Therapeutics Inc USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID FOR THE TREATMENT OF GASTROINTESTINAL TRACT DISORDERS AND AS AN IMMUNOMODULATING AGENT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US8222293B2 (en) 2004-05-24 2012-07-17 Regents of the University of Carolina Treating learning deficits with inhibitors of Hmg CoA reductase
WO2009033818A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2011106692A2 (en) 2010-02-25 2011-09-01 Northwestern University Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
EP2621475A1 (en) 2010-10-02 2013-08-07 Link Research&Grants Corporation Treatment of tinnitus and related auditory dysfunctions
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
CA2862816A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
TW201606304A (zh) * 2013-09-09 2016-02-16 亞克柏拉有限公司 測定治療反應之方法
US20150224164A1 (en) 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
ES2882126T3 (es) 2014-11-07 2021-12-01 Univ Northwestern Inhibición de ornitina aminotransferasa con análogos de GABA para el tratamiento de carcinoma hepatocelular
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
BR112018007026B1 (pt) 2015-10-09 2022-06-21 Northwestern University Composto, composição farmacêutica, e usos do composto
US10632088B2 (en) 2016-10-10 2020-04-28 Northwestern University Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
IL310065A (en) 2017-02-08 2024-03-01 Ovid Therapeutics Inc Methods for treating seizure disorders and Prader-Willi syndrome
JP7258902B2 (ja) * 2017-11-14 2023-04-17 エスケー バイオファーマスティカルズ カンパニー リミテッド 脆弱ｘ症候群、アンジェルマン症候群又はレット症候群を含む発達障害の軽減又は治療のためのカルバメート化合物の使用
KR102791742B1 (ko) 2018-05-25 2025-04-03 노오쓰웨스턴 유니버시티 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산의 합성을 위한 공정
EP3813816B1 (en) 2018-06-07 2023-06-07 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome

Also Published As

Publication number Publication date
ES2948263T3 (es) 2023-09-07
IL304270B2 (en) 2024-10-01
MX2020013290A (es) 2021-04-29
CA3102786A1 (en) 2019-12-12
EP3813816A1 (en) 2021-05-05
MX2023006497A (es) 2023-06-21
AU2019280980B2 (en) 2025-02-27
KR102744830B1 (ko) 2024-12-19
US12285397B2 (en) 2025-04-29
CN112770739A (zh) 2021-05-07
US20230255914A1 (en) 2023-08-17
IL304270A (en) 2023-09-01
KR20210035802A (ko) 2021-04-01
EP3813816A4 (en) 2021-06-23
US20190374492A1 (en) 2019-12-12
JP2021527053A (ja) 2021-10-11
CN112770739B (zh) 2023-12-12
WO2019236938A1 (en) 2019-12-12
US20210100763A1 (en) 2021-04-08
IL279220B2 (en) 2023-12-01
IL279220B1 (en) 2023-08-01
IL279220A (en) 2021-01-31
EP3813816B1 (en) 2023-06-07
IL304270B1 (en) 2024-06-01
JP7387179B2 (ja) 2023-11-28
EP3813816C0 (en) 2023-06-07
US10813899B2 (en) 2020-10-27
AU2019280980A1 (en) 2021-01-07
US11660277B2 (en) 2023-05-30

Similar Documents

Publication Publication Date Title
IL289975A (en) Use of cannabidiol in the treatment of dravet syndrome
GB201915517D0 (en) Use of cannabidiol preparations in the treatment of fragile X syndrome
AU2018295515A1 (en) Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
ZA201801300B (en) Composition and medical device comprising acetylsalicylic acid for the treatment of human papilloma virus skin infections
IL304270A (en) Use of (s)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1s, 3s)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders
IL268125A (en) Pridopidine for the treatment of fragile x syndrome
IL269555A (en) Glatiramer depot systems for treating progressive forms of multiple sclerosis
EP3280722B8 (en) Antimicrobial peptides and their use for the treatment of topical infections
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
EP3758693A4 (en) USE OF (1S, 3S) -3-AMINO-4- (DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND (S) -3-AMINO-4- (DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1 -CARBOXYLIC IN THE TREATMENT OF EYE DISORDERS
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
ZA202104891B (en) Liposomial eye drops solution and uses thereof for the treatment of dry eye syndrome
IL288531A (en) Broad-spectrum antibacterial pharmaceutical formulations comprising lyses and methods of using them
EP4005587C0 (en) Pharmaceutical composition for treating levodopa-induced dyskinesia or for blocking its progression
IL277253A (en) Formulations of cyclosporine and use in the treatment of obliterative bronchiolitis syndrome
IL285265A (en) Triamtrin or nolatrexad for use in the treatment of phenylketonuria
HUE051948T2 (hu) Protokollok és eljárások sclerosis multiplex kezelésére ofatumumab alkalmazásával
IL283619A (en) Compounds with pde9a prophylactic activity, and their medicinal use
WO2017100600A3 (en) Methods and systems for stiffening of tissue for improved processing
WO2016072854A3 (en) Pantothenamide analogues
WO2019025803A3 (en) ANTIMICROBIAL COMPOSITION
SG11202000506VA (en) Formulation comprising nanostructured, biocompatible and biocatalytic material for the treatment of wounds and infections
HK40045205A (en) Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
HK40074743A (en) Methylthioninium for use in the treatment of synaptopathies
HK40075457A (en) Use of cannabidiol in the treatment of dravet syndrome